Clinical trials: Acute Phase
Acute Bronchitis
Efficacy and Safety of GHX02 in the Treatment of Acute Bronchitis
This study is a phase 2, multicentre, dose-finding, double-blind, randomized placebo-controlled trial to evaluate the efficacy and safety of two different doses of GHX02, compared with placebo, for acute bronchitis.
- Trial name
- NCT03310385
- Testing
- GHX02
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Daejeon University
Acute Myeloid Leukemia, Myelodysplastic Syndromes
ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant
This is a single-center Phase 1 trial of 20 patients with AML/MDS. Eligible patients will be enrolled following an informed consent between 6-20 weeks after allogeneic hematopoietic stem cell transplant.
- Trial name
- NCT03932643
- Testing
- ONC-201
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Nebraska
Disseminated Intravascular Coagulation (DIC)
A Phase 3 Clinical Study of KW-3357 in Patients With DIC
To evaluate the efficacy and safety of KW-3357 with concomitant use of heparin using multi-center, non-comparative, open-label method in patients diagnosed as disseminated intravascular coagulation (DIC) by Japanese Association…
- Trial name
- 3357-006 (NCT01384409)
- Testing
- KW-3357
- Where
- Japan
- Volunteers
- 5 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Leukemia
Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 in treating children who have undergone bone marrow transplantation…
- Trial name
- NCT00009698
- Testing
- aldesleukin
- Where
- 119 sites in United States, Australia and 4 more
- Volunteers
- 1 people
- Sponsor
- Children's Oncology Group
AML, Adult Recurrent, ALL, Recurrent, Adult
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
The goal of this clinical trial is to test BSB-1001 which is a new type of cellular therapy to treat blood cancers (AML, ALL and MDS).
- Conditions
- AML, Adult Recurrent, ALL, Recurrent, Adult, MDS
- Trial name
- NCT06704152
- Testing
- SOC + BSB-1001 Dose Escalation Cohort, SOC+BSB-1001 Expansion Dose
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- BlueSphere Bio, Inc
Pulmonary Disease, Chronic Obstructive
Nutritional Status in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
A cross sectional observation study of body composition in COPD patients consecutively hospitalized with acute exacerbation.
- Trial name
- NCT03709498
- Where
- Greece
- Volunteers
- 60 people
- Sponsor
- Evangelismos Hospital
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies
This phase I multicenter feasibility trial is studying the safety and potential efficacy of infusing ex vivo expanded cord blood progenitors with one unmanipulated umbilical cord blood unit for transplantation following…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00343798
- Testing
- cyclophosphamide, fludarabine phosphate, cyclosporine
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Fred Hutchinson Cancer Center
T-cell Acute Lymphoblastic Leukemia
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.
- Trial name
- NCT05289687
- Testing
- Daratumumab / Hyaluronidase Injection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Eastern Cooperative Oncology Group
Acute Ischemic Stroke (AIS)
Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke
The objectives of this study are to assess the safety, tolerability and local tolerance, and to investigate the plasma levels and terminal elimination half life of MCI-186, and to review the routine clinical and neurological…
- Trial name
- NCT00821821
- Testing
- MCI-186
- Where
- 3 sites in Finland, Netherlands and 1 more
- Volunteers
- 36 people
- Sponsor
- Shionogi
B-ALL, Leukemia
A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
This is a phase 1, open-label study to evaluate the safety and efficacy of CD19 t-haNK in patients with B-cell acute lymphoblastic leukemia. Up to 10 patients will receive at least 1 dose of study drug.
- Trial name
- NCT07556757
- Testing
- CD19 t-haNK
- Where
- 2 sites in South Africa
- Volunteers
- 4 people
- Sponsor
- ImmunityBio, Inc.
Bladder Cancer, Cervical Cancer
Bupropion in Helping Adults Stop Smoking
RATIONALE: Bupropion may help people stop smoking by decreasing the symptoms of nicotine withdrawal. Giving bupropion over a longer period of time may be effective in helping people stop smoking.
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00534001
- Testing
- bupropion hydrochloride
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Roswell Park Cancer Institute
Leukemia, Lymphoma
Radiation Therapy and Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With High-Grade Lymphoma or Acute Lymphoblastic Leukemia
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00004898
- Testing
- filgrastim, cyclophosphamide, etoposide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Northwestern University
Acute Myeloid Leukemia
CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
The trial is a randomized, open-label phase II study comparing CPX-351 vs conventional intensivechemotherapy in patients with newly diagnosed de novo AML and intermediate- or adverse-risk genetics
- Trial name
- ALFA2101 (NCT05260528)
- Testing
- Cytarabine and Idarubicin, CPX-315
- Where
- 35 sites in France
- Volunteers
- 248 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
The primary objective was to evaluate the effect of blinatumomab on overall survival when compared to standard of care (SOC) chemotherapy.
- Trial name
- NCT02013167
- Testing
- Blinatumomab, Standard of Care Chemotherapy
- Where
- 117 sites in United States, Australia and 19 more
- Volunteers
- 405 people
- Sponsor
- Amgen
Gout Attack
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout Attack
The primary goal of the study was to evaluate the parameters of efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of RPH-104 in adult patients with acute gout attack.
- Trial name
- NCT04067492
- Testing
- RPH - 104, Voltaren®
- Where
- 11 sites in Russia
- Volunteers
- 47 people
- Sponsor
- R-Pharm
Ischemic Stroke; Ischemic Attack, Transient
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
- Trial name
- LIBREXIA-STROK (NCT05702034)
- Testing
- Milvexian
- Where
- 880 sites in United States, Argentina and 45 more
- Volunteers
- 12,523 people
- Sponsor
- Janssen Research & Development, LLC
Acute Myeloid Leukemia (AML)
Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug UniCAR02-T-CD123 in patients with hematologic and…
- Trial name
- NCT04230265
- Testing
- Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), TM123 (IMP)
- Where
- 10 sites in Germany, Netherlands
- Volunteers
- 32 people
- Sponsor
- AvenCell Europe GmbH
Covid-19
Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome (ARDS) is the major cause of death in the COVID-19 pandemic. In this trial, the safety and efficacy of Mesenchymal Stem Cells (MSC) for the treatment of ARDS in COVID-19 patients will be…
- Trial name
- NCT04366063
- Testing
- Cell therapy protocol 1, Cell therapy protocol 2
- Where
- Iran
- Volunteers
- 60 people
- Sponsor
- Royan Institute
Hereditary Angioedema
A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)
This study is being conducted to evaluate the efficacy and safety of icatibant compared to placebo in patients experiencing acute attacks of hereditary angioedema (HAE).
- Trial name
- NCT00912093
- Testing
- Icatibant
- Where
- 64 sites in United States, Australia and 7 more
- Volunteers
- 98 people
- Sponsor
- Shire
Double Cord Blood Transplant, Acute Myelogenous Leukemia
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation
The purpose of this study is to evaluate the effect of TXA127 on neutrophil and platelet counts in adult patients who have undergone a double cord blood transplant.
- Conditions
- Double Cord Blood Transplant, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Myelofibrosis
- Trial name
- USBTXA127CBT (NCT01300611)
- Testing
- TXA127 300 mcg/kg/day, TXA127 1000 mcg/kg/day
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Tarix Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.